A retrospective study to assess safety of or apixaban in patients with chronic renal disease Stage V and end stage renal disease on dialysis for Venous Thromboembolism
Latest Information Update: 24 Jan 2019
Price :
$35 *
At a glance
- Drugs Apixaban (Primary) ; Warfarin
- Indications Venous thromboembolism
- Focus Adverse reactions
- 24 Jan 2019 New trial record
- 04 Dec 2018 Results presented at the 60th Annual Meeting and Exposition of the American Society of Hematology